Advertisement
AQB or BCRX or SRRK
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AQB’s FA Score shows that 0 FA rating(s) are green whileBCRX’s FA Score has 1 green FA rating(s), and SRRK’s FA Score reflects 0 green FA rating(s).
- AQB’s FA Score: 0 green, 5 red.
- BCRX’s FA Score: 1 green, 4 red.
- SRRK’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AQB’s TA Score shows that 4 TA indicator(s) are bullish while BCRX’s TA Score has 3 bullish TA indicator(s), and SRRK’s TA Score reflects 3 bullish TA indicator(s).
- AQB’s TA Score: 4 bullish, 5 bearish.
- BCRX’s TA Score: 3 bullish, 5 bearish.
- SRRK’s TA Score: 3 bullish, 7 bearish.
Price Growth
AQB (@Agricultural Commodities/Milling) experienced а -1.40% price change this week, while BCRX (@Pharmaceuticals: Generic) price change was +3.69% , and SRRK (@Biotechnology) price fluctuated -0.27% for the same time period.
The average weekly price growth across all stocks in the @Agricultural Commodities/Milling industry was +3.33%. For the same industry, the average monthly price growth was +7.98%, and the average quarterly price growth was -10.43%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +2.56%. For the same industry, the average monthly price growth was +23.25%, and the average quarterly price growth was +9.77%.
The average weekly price growth across all stocks in the @Biotechnology industry was +0.78%. For the same industry, the average monthly price growth was +90.18%, and the average quarterly price growth was +2050.65%.
Reported Earning Dates
BCRX is expected to report earnings on Jul 30, 2026.
SRRK is expected to report earnings on Aug 12, 2026.
Industries' Descriptions
@Agricultural Commodities/Milling (+3.33% weekly)The Agricultural Commodities/Milling industry includes companies that are involved in farming activities, such as crop production, livestock management and animal feed, for commercial purposes. The industry includes a wide range of operations from growing corn, to grain and oilseed processing to the operation of flour mills. Changes in consumer tastes is one of the critical factors influencing what products are grown and raised in this industry. Potential risks to the business include climate change and fluctuations in global prices of agricultural products. Archer-Daniels-Midland Company, Elanco Animal Health, Inc., Bunge Limited and Canopy Growth Corporation are some of the biggest U.S. companies operating in this industry.
@Pharmaceuticals: Generic (+2.56% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
@Biotechnology (+0.78% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| AQB | BCRX | SRRK | |
| Capitalization | 5.15M | 2.21B | 5.29B |
| EBITDA | -3.49M | -377.5M | -399.75M |
| Gain YTD | 3.903 | 11.795 | 0.295 |
| P/E Ratio | N/A | 7.46 | N/A |
| Revenue | 0 | 886M | 0 |
| Total Cash | 441K | 238M | 480M |
| Total Debt | 3.79M | 818M | 206M |
AQB | BCRX | SRRK | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 78 | 61 | 63 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 54 Fair valued | 20 Undervalued | 66 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | 74 | |
SMR RATING 1..100 | 100 | 100 | 99 | |
PRICE GROWTH RATING 1..100 | 48 | 57 | 52 | |
P/E GROWTH RATING 1..100 | 100 | 47 | 100 | |
SEASONALITY SCORE 1..100 | 50 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BCRX's Valuation (20) in the Biotechnology industry is somewhat better than the same rating for AQB (54) and is somewhat better than the same rating for SRRK (66). This means that BCRX's stock grew somewhat faster than AQB’s and somewhat faster than SRRK’s over the last 12 months.
SRRK's Profit vs Risk Rating (74) in the Biotechnology industry is in the same range as BCRX (100) and is in the same range as AQB (100). This means that SRRK's stock grew similarly to BCRX’s and similarly to AQB’s over the last 12 months.
SRRK's SMR Rating (99) in the Biotechnology industry is in the same range as BCRX (100) and is in the same range as AQB (100). This means that SRRK's stock grew similarly to BCRX’s and similarly to AQB’s over the last 12 months.
AQB's Price Growth Rating (48) in the Biotechnology industry is in the same range as SRRK (52) and is in the same range as BCRX (57). This means that AQB's stock grew similarly to SRRK’s and similarly to BCRX’s over the last 12 months.
BCRX's P/E Growth Rating (47) in the Biotechnology industry is somewhat better than the same rating for AQB (100) and is somewhat better than the same rating for SRRK (100). This means that BCRX's stock grew somewhat faster than AQB’s and somewhat faster than SRRK’s over the last 12 months.
| AQB | BCRX | SRRK | |
|---|---|---|---|
| RSI ODDS (%) | N/A | N/A | 2 days ago 88% |
| Stochastic ODDS (%) | 2 days ago 70% | 2 days ago 82% | 2 days ago 80% |
| Momentum ODDS (%) | 2 days ago 90% | 2 days ago 81% | 2 days ago 90% |
| MACD ODDS (%) | 2 days ago 83% | 2 days ago 81% | 2 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 88% | 2 days ago 75% | 2 days ago 87% |
| TrendMonth ODDS (%) | 2 days ago 74% | 2 days ago 83% | 2 days ago 88% |
| Advances ODDS (%) | 17 days ago 73% | 2 days ago 76% | 19 days ago 80% |
| Declines ODDS (%) | 2 days ago 89% | 4 days ago 80% | 6 days ago 88% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 89% | 2 days ago 83% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 83% | 2 days ago 90% |
Advertisement